Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on April 30, 2026. The filing discloses the appointment of a new Chief Financial Officer and details the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Appointment: Darren Snellgrove has been appointed as Chief Financial Officer (CFO), effective June 8, 2026.
- Leadership Transition: Current Interim CFO David Ramsay will assume an advisory role to assist during the transition period.
- Compensation Structure:
- Base Salary: $670,000 annually.
- Sign-on Bonus: $350,000 cash (subject to repayment if terminated within 24 months).
- Annual Bonus Target: 50% of base salary (prorated for 2026).
- Equity Awards (Total Grant Date Value: $7.2 million):
- $3.2 million in Restricted Stock Units (RSUs) to make the executive whole for forfeited J&J equity; vests one-third annually over three years.
- $4.0 million in stock options; vests 25% after one year, then monthly over three years.
- Future Incentives: Eligible for long-term incentive awards starting in 2027 with a minimum total grant date value of $4.0 million.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or management commentary on business operations. The primary risk disclosed relates to the repayment of the sign-on bonus if the new CFO voluntarily terminates employment or is terminated for misconduct within 24 months of hire.
Investor Verification Checklist
- Verify the effective start date of the new CFO (June 8, 2026) and the transition plan for the Interim CFO.
- Review the vesting schedules for the $7.2 million equity package, specifically the distinction between the "make-whole" RSUs and performance-based stock options.
- Confirm the terms of the $350,000 sign-on bonus repayment clause.
- Check for any subsequent filings regarding the impact of this executive change on the company's strategic direction.